News articles about Evogene (NASDAQ:EVGN) have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Evogene earned a daily sentiment score of 0.02 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.4968235343142 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Evogene (NASDAQ EVGN) opened at $4.00 on Friday. Evogene has a 12 month low of $2.66 and a 12 month high of $5.84. The stock has a market cap of $103.00, a price-to-earnings ratio of -4.82 and a beta of 0.55.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/14/evogene-evgn-given-daily-coverage-optimism-score-of-0-02.html.
Evogene Company Profile
Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.